The F.D.A. is belatedly investigating production of the blood thinner heparin by Baxter International at a Chinese plant the agency forgot to inspect. F.D.A. regulators made a trip to the plant last week and released a heavily redacted report about a drug now linked to as many as 21 deaths and more than 400 adverse reactions. The New York Time’s Walt Bogdanich lays out the multiple places that the problem could have started — at the point of unregulated Chinese family workshops, wholesalers or the factory itself. Baxter International has recalled essentially all of their blood thinning products as the disconcerting probe into the blood thinner supply system continues.  Read Bogdanich here.

Comment RSS - You can skip to the end and leave a response. Pinging is currently not allowed.